课题基金 / 基金详情

Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescents

Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescents
解决一群围产期感染的肯尼亚儿童和青少年的艾滋病毒耐药性研究空白
批准号:
10630333
负责人:
Rami Kantor
金额:
$69.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-06-27 至 2025-05-31

项目摘要

项目成果

Rami Kantor的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 艾滋病毒耐药性可能危及联合国艾滋病规划署的90-90-90治疗目标,是 可持续的抗逆转录病毒治疗取得成功。尽管根据患者指南建议进行耐药性检测 在发达国家,对其的理解存在研究空白;基因-表型 HIV-1不同亚型之间的相关性、少数人耐药变异与 治疗结果,以及基因型和治疗成功或失败之间不一致的原因仍然存在 不清楚。这些研究差距在资源有限、药物有限的情况下尤其令人担忧 和次优监测是常见的;在儿童和青少年中,患有 需要终身治疗,他们的艾滋病毒-1RNA水平更高,治疗差距更大,接受治疗的人更少, 更低的抑制率,有限的配方和更多的不坚持。我们研究的长期目标是 团队正在为改善儿童青少年的临床疾病管理提供新的证据 在资源有限的情况下应对艾滋病毒。这项提议的目的是解决现有的抗药性 先前建立的、经过仔细描述的499名儿童和青少年队列中的研究空白 肯尼亚的艾滋病毒携带者。要做到这一点,我们将利用我们与学术模型的成功合作,提供 肯尼亚获得医疗保健(AMPATH),这是撒哈拉以南非洲最大的艾滋病毒项目之一,以及 独特地利用我们正在进行的R01 AI120792关于围产期感染儿童的现有资源,以及 AMPATH的青少年(MPI Kantor和Vreeman)。我们假设,全面调查 不同非B亚型中的基因表型和耐药治疗结果不一致将得到解决 其中一些现有的研究差距,并在最需要的环境中优化患者护理。我们会 解决这一假设的目的如下:(1)调查基因-表型相关性;(2)评估 在存在“易感基因”的情况下治疗失败的原因;以及(3)评估以下情况的原因 在存在“耐药基因”的情况下,治疗取得成功。为了实现这些目标,我们将使用已经 现有的肯尼亚儿童和青少年队列样本(2016-2018年间收集) 与非B亚型生活(目标1);纵向跟踪队列四年(目标2和3);采集血液 每两年抽样一次,并评估遵守情况;确定有资格获得建议的额外费用的参与者 调查;进行体外表型鉴定以检查基因类型和表型之间的相关性;以及 对RNA和DNA进行全长下一代测序,以研究少数耐药变异和 可供选择的抗性机制。这项建议的创新之处在于研究的队列的独特性, 全面建议的科学调查、研究设计和不协调基因的评估- 治疗结果情景。这些调查和直接解决现有的知识差距 在具有不同非B亚型的特别脆弱人群中,艾滋病毒-1耐药性将具有很高的 对改善艾滋病毒携带者儿童、青少年和成人治疗结果的影响。
英文摘要
PROJECT SUMMARY HIV drug resistance may compromise the UNAIDS 90-90-90 treatment goals and is a major hurdle to sustainable antiretroviral therapy success. Though resistance testing is recommended by guidelines for patient care in developed countries, there are existing research gaps in its understanding; genotypic-phenotypic correlations in diverse HIV-1 subtypes, the relationship between minority drug resistance variants and treatment outcomes, and reasons for discordances between genotype and treatment success or failure remain unclear. These research gaps are of particular concern in resource-limited settings, where limited medications and sub-optimal monitoring are common; and in children and adolescents, a vulnerable population with the need for life-long therapy, who have higher levels of HIV-1 RNA, a wider treatment gap with fewer on therapy, lower rates of suppression, limited formulations and more non-adherence. The long-term goal of our research team is to provide new evidence to improve the clinical disease management children and adolescents living with HIV in resource-limited settings. The purpose of this proposal is to address existing drug resistance research gaps in a previously established, carefully characterized cohort of 499 children and adolescents living with HIV in Kenya. To do this, we will use our successful collaboration with the Academic Model Providing Access to Healthcare (AMPATH) in Kenya, one of the largest HIV programs in sub-Saharan Africa, and uniquely leverage existing resources from our ongoing R01 AI120792 on perinatally-infected children and adolescents at AMPATH (MPI Kantor and Vreeman). We hypothesize that comprehensive investigations of genotypic-phenotypic and resistance-treatment outcome discordances in diverse non-B subtypes will resolve some of these existing research gaps and optimize patient care in settings where it is most needed. We will address this hypothesis with the following Aims: (1) Investigate genotype-phenotype correlations; (2) Evaluate etiologies for treatment failure in the presence of a ‘susceptible genotype’; and (3) Evaluate etiologies for treatment success in the presence of a ‘resistant genotype’. To achieve these aims, we will use already available samples (collected between 2016-2018) from the existing cohort of Kenyan children and adolescents living with non-B subtypes (Aim 1); longitudinally follow the cohort for four years (Aims 2 and 3); collect blood samples bi-annually and assess adherence; identify participants that are eligible for proposed additional investigations; conduct in vitro phenotyping to examine genotypic-phenotypic correlations; and perform near full-length next generation sequencing on RNA and DNA to investigate minority resistance variants and alternative mechanisms of resistance. The proposal is innovative in the uniqueness of the cohort studied, the comprehensive proposed scientific investigations, and study design and evaluation of discordant genotype- treatment outcomes scenarios. These investigations and directly addressing the existing knowledge gaps in HIV-1 drug resistance in a particularly-vulnerable population with diverse non-B subtypes, will have a high impact on improving treatment outcomes in children, adolescents, and adults living with HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV Treatment Failure and Drug Resistance in Western Kenyan Children
Real Time Phylogeny and Contact Tracing to Disrupt HIV Transmission
  • 批准号:
    10335147
  • 项目类别:
  • 资助金额:
    $64.77万
  • 财政年份:
    2018
  • 负责人:
    Rami Kantor
  • 依托单位:
Real Time Phylogeny and Contact Tracing to Disrupt HIV Transmission
  • 批准号:
    10097973
  • 项目类别:
  • 资助金额:
    $66.16万
  • 财政年份:
    2018
  • 负责人:
    Rami Kantor
  • 依托单位:
HIV Treatment Failure and Drug Resistance in Western Kenyan Children
海外基金